share_log

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

NeuroBo Pharmaceuticals | 8-K: Current report

NeuroBo Pharmaceuticals | 8-K:重大事件
美股SEC公告 ·  03/13 08:33
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息